Cefepime Mylan

Valsts: Jaunzēlande

Valoda: angļu

Klimata pārmaiņas: Medsafe (Medicines Safety Authority)

Aktīvā sastāvdaļa:

Cefepime dihydrochloride monohydrate 575.9mg equivalent to 500 mg cefepime free base;  

Pieejams no:

Viatris Limited

SNN (starptautisko nepatentēto nosaukumu):

Cefepime dihydrochloride monohydrate 575.9 mg (equivalent to 500 mg cefepime free base)

Deva:

500 mg

Zāļu forma:

Powder for injection

Kompozīcija:

Active: Cefepime dihydrochloride monohydrate 575.9mg equivalent to 500 mg cefepime free base   Excipient: Arginine

Vienības iepakojumā:

Vial, glass, single dose, Type 1 clear glass vial with grey bromo butyl rubber stopper, 500 mg

Klase:

Prescription

Receptes veids:

Prescription

Ražojis:

Aurobindo Pharma Limited

Ārstēšanas norādes:

CEFEPIME Mylan is indicated in adults for the treatment of the infections listed below when caused by susceptible bacteria. · Lower respiratory tract infections, including pneumonia and bronchitis. · Urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. · Skin and skin structure infections. · Septicaemia. · Intra-abdominal infections, including peritonitis and biliary tract infections. · Empiric treatment of febrile neutropenia.

Produktu pārskats:

Package - Contents - Shelf Life: Vial, glass, single dose, Type 1 clear glass vial with grey bromo butyl rubber stopper - 500 mg - 2 years from date of manufacture stored at or below 25°C protect from light 24 hours reconstituted stored at or below 25°C protect from light 168 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) protect from light

Autorizācija datums:

2009-06-17